Pemphigus Completed Phase 2 / 3 Trials for Rituximab (DB00073)

IndicationStatusPhase
DBCOND0001806 (Pemphigus)Completed2 / 3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00213512Effect of Anti CD20 in Pemphigus DeseaseHealth Services Research